A landmark Oxford-led analysis of 1.8 million people has found that non-meat diets significantly slash the risk of several cancers, including a 31% drop in multiple myeloma.

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...

Robert F. Kennedy Jr. and his subordinates want Americans to have more conversations with their physicians. But they also can ...

Arun Menawat, Chairman & CEO, emphasized the completion of recruitment for CAPTAIN, the first multicenter, randomized, controlled trial comparing a new technology to robotic radical prostatectomy, ...